Skip to main content

Table 2 Univariate and Multivariate Cox proportional hazards models to predict survival in patients with unresectable pancreatic cancer

From: Prognostic nomogram for patients with unresectable pancreatic cancer treated with gemcitabine plus nab–paclitaxel or FOLFIRINOX: A post–hoc analysis of a multicenter retrospective study in Japan (NAPOLEON study)

Variables

Univariate analysis

Multivariate analysis

 

HR

95%CI

P–value

HR

95%CI

P–value

Age

      

<60

reference

     

60–70

0.99

0.74 – 1.35

0.998

1.07

0.77 – 1.50

0.674

>70

0.99

0.70 – 1.39

0.936

1.08

0.73 – 1.59

0.710

Sex

      

F

reference

     

M

0.92

0.71 – 1.19

0.517

0.96

0.71 – 1.28

0.766

ECOG PS

      

0

reference

     

1

1.54

1.16 – 2.04

0.003

1.43

1.03 – 1.93

0.033

2 or more

2.22

1.30 – 3.79

0.003

2.52

1.34 – 4.71

0.004

Body mass index

      

<22

reference

     

≥22

1.01

0.77 – 1.30

0.969

0.98

0.73 – 1.31

0.880

Tumor resection

      

no

reference

     

yes

0.73

0.50 – 1.07

0.103

0.71

0.45 – 1.12

0.142

Pancreatic tumor location

     

Head

reference

     

Body

1.04

0.78 – 1.39

0.800

0.89

0.63 – 1.25

0.496

Tail

1.14

0.81 – 1.61

0.461

0.72

0.47 – 1.10

0.133

Tumor size

      

<20

reference

     

20 – 40

0.99

0.67 – 1.47

0.979

0.94

0.60 – 1.47

0.775

>40

1.39

0.91 – 2.11

0.125

0.88

0.54 – 1.43

0.605

Histology

      

Adenocarcinoma

reference

     

Others

1.09

0.75 – 1.56

0.656

1.26

0.83 – 1.90

0.280

Liver metastasis

      

No

reference

     

Yes

2.08

1.61 – 2.69

< 0.001

1.85

1.26 – 2.73

0.002

Peritoneal metastasis

      

No

reference

     

Yes

0.95

0.68 – 1.31

0.742

0.91

0.57 – 1.44

0.674

Lung metastasis

      

No

reference

     

Yes

1.39

0.95 – 1.31

0.09

1.40

0.86 – 2.29

0.176

Number of metastasis

      

0 or 1

reference

     

2 or more

1.59

1.21 – 2.09

< 0.001

1.17

0.80 – 1.71

0.422

Ascites

      

No

reference

     

Yes

1.52

1.12 – 2.05

0.007

1.37

0.93 – 2.00

0.112

Albumin (g/dL), n (%)

      

>4

reference

     

3 – 4

0.82

0.54 – 1.24

0.349

1.45

0.88 – 2.37

0.144

<3

0.56

0.36 – 0.88

0.012

1.29

0.72 – 2.27

0.399

LDH (U/L), n (%)

      

<240

reference

     

240 – 360

1.91

1.32 – 2.77

< 0.001

1.51

0.97 – 2.33

0.065

>360

2.90

1.36 – 6.19

0.006

2.88

1.35 – 6.82

0.007

CRP (mg/dL), n (%)

      

<0.3

reference

     

0.3–3.0

1.45

1.09 – 1.92

0.010

1.12

0.81 – 1.55

0.503

>3.0

3.04

2.09 – 4.43

< 0.001

2.04

1.23 – 3.36

0.005

CA19–9 (U/mL), n (%)

      

<37

reference

     

37 – 370

1.24

0.84 – 1.84

0.285

1.18

0.77 – 1.80

0.441

>370

1.91

1.36 – 2.68

< 0.001

1.45

1.01 – 2.07

0.043

AJCC TNM stage, n (%)

     

III

reference

     

IV

1.73

1.24 – 2.44

0.001

1.14

0.70 – 1.86

0.606

First line regimen, n (%)

      

FFX

reference

     

GnP

0.86

0.66 – 1.11

0.249

0.99

0.72 – 1.36

0.942

  1. Abbreviations: HR Hazard ratio, CI Confidence interval, ECOG PS Eastern Cooperative Oncology Group performance status, LDH lactate dehydrogenase, CRP C–reactive protein, CA19–9 carbohydrate antigen 19–9, AJCC American Joint Committee on Cancer, GnP gemcitabine plus nab–paclitaxel, FFX FOLFIRINOX